ProQR Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell PRQR and other ETFs, options, and stocks.About PRQR
ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J.
CEODaniel Anton de Boer
CEODaniel Anton de Boer
Employees157
Employees157
HeadquartersLeiden, Zuid-Holland
HeadquartersLeiden, Zuid-Holland
Founded2012
Founded2012
Employees157
Employees157
PRQR Key Statistics
Market cap164.87M
Market cap164.87M
Price-Earnings ratio-5.35
Price-Earnings ratio-5.35
Dividend yield—
Dividend yield—
Average volume182.91K
Average volume182.91K
High today$2.12
High today$2.12
Low today$1.99
Low today$1.99
Open price$2.01
Open price$2.01
Volume185.51K
Volume185.51K
52 Week high$3.29
52 Week high$3.29
52 Week low$1.11
52 Week low$1.11
PRQR News
TipRanks 19h
ProQR Therapeutics Announces Board Nomination and AGM - TipRanks.com - TipRanksProQR Therapeutics BV (PRQR) has released an update. ProQR Therapeutics has announced their upcoming Annual General Meeting for shareholders on May 22, 2024, a...
TipRanks 5d
ProQR Solidifies Lead in RNA Therapy Innovation - TipRanks.com - TipRanksProQR Therapeutics BV (PRQR) has released an update. ProQR Therapeutics has announced the successful defense of their key Axiomer RNA editing platform patent,...
TipRanks 5d
ProQR Therapeutics defends against challenge to Axiomer IP portfolioProQR Therapeutics announced it has defended against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer. The opposition wa...
Analyst ratings
71%
of 7 ratingsBuy
71.4%
Hold
28.6%
Sell
0%